GlassScriptPhysician profile
Andrew S Kim
NPI 1053340463
$103,924.90
in general payments reported to CMS, 2019-2025
32 companies · $1,482 in 2025
The $1,482 reported for 2025 was more than what a typical Allergy & Immunology provider received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $30K · 2020: $17K · 2021: $30K · 2022: $24K · 2023: $575 · 2024: $366 · 2025: $1,482.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,423.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,422.67 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $36,632.02 | 2019-2025 | Dupixent |
| Optinose US, INC. | $25,566.72 | 2019-2025 | |
| Genzyme Corporation | $22,528.04 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $14,506.77 | 2019-2025 | Tezspire, Airsupra, Fasenra |
| Glaxosmithkline, LLC. | $1,306.45 | 2019-2025 | Nucala, Trelegy Ellipta |
| Novartis Pharmaceuticals Corporation | $540.07 | 2021-2025 | |
| Pfizer INC. | $290.43 | 2019-2024 | |
| Amgen INC. | $284.43 | 2021-2025 | Tezspire |
| Kaleo, INC. | $264.53 | 2019-2022 | |
| Alk-Abello, INC | $260.77 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $198.40 | 2019-2022 | |
| Genentech USA, INC. | $172.69 | 2019-2022 | |
| Csl Behring | $157.81 | 2020-2025 | Andembry, Haegarda |
| Abbvie INC. | $145.27 | 2022-2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $134.36 | 2021-2025 | Cuvitru |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $103.56 | 2021-2025 | Opzelura |
| Regeneron Pharmaceuticals, INC. | $100.83 | 2019 | |
| Gilead Sciences, INC. | $82.52 | 2021 | |
| Ars Pharmaceuticals Operations, INC. | $81.93 | 2025 | Neffy |
| Ionis Pharmaceuticals, INC. | $74.69 | 2025 | Dawnzera |
| Aimmune Therapeutics, INC. | $67.63 | 2021-2022 | |
| Greer Laboratories, INC. | $61.97 | 2021-2025 | Oralair |
| Teva Pharmaceuticals USA, INC. | $59.26 | 2021 | |
| Biocryst US Sales Co., LLC | $58.27 | 2022-2023 | Orladeyo |
| Boehringer Ingelheim Pharmaceuticals, INC. | $57.65 | 2019-2021 | |
| Grifols USA, LLC | $48.24 | 2022-2023 | Prolastin-C Liquid |
| Pharming Healthcare, INC. | $37.79 | 2021-2022 | |
| Azurity Pharmaceuticals, INC. | $25.33 | 2025 | Alvesco |
| Galderma Laboratories, L.P. | $22.11 | 2025 | Nemluvio |
| Leo Pharma INC. | $22.01 | 2022 | |
| Horizon Therapeutics Plc | $18.19 | 2021 | |
| Bard Peripheral Vascular, INC. | $14.16 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andrew Kim listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.